Hailee F. Scelsi
Research Subjects
Hailee F. Scelsi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Raquel L. Lieberman
School of Chemistry & Biochemistry Georgia Institute of Technology Atlanta Georgia USA
4 shared publications - Brett M. Barlow
School of Chemistry & Biochemistry, Georgia Institute of Technology , 901 Atlantic Dr. NW, Atlanta, GA 30332-0400 , USA
2 shared publications - Kamisha R. Hill
School of Chemistry and Biochemistry, Georgia Institute of Technology 1 , Atlanta, GA 30332
2 shared publications - Cassie S. Mitchell
Department of Mathematics, Brigham Young University
1 shared publication - Donna M. Peters
University of Wisconsin 2 Department of Pathology and Laboratory Medicine Madison, WI 53705
1 shared publication Elijah T. Dunn
School of Chemistry and Biochemistry, Georgia Institute of Technology 1 , Atlanta, GA 30332
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 19 (10)
Trabecular meshwork cellular mis-trafficking of near-native and premature stop variants in glaucoma-relevant myocilin
Mutations in the myocilin olfactomedin (OLF) domain can cause vision loss in glaucoma by inducing protein misfolding in trabecular meshwork cells. However, not all mutations are causal for the disease. Here, we compare the cellular behaviors of two variants with uncertain contribution to glaucoma – namely, the missense variant A427T and premature stop variant Q368X – to those of wild type (WT) and disease variant Y437H. When expressed in an inducible immortalized trabecular meshwork cell line, inhibition of the proteasome rerouted WT myocilin from endoplasmic reticulum-associated degradation to autophagy. By contrast, neither Y437H, A427T nor Q368X could be rerouted for degradation. Conversely, inhibition of autophagy caused accumulation of WT myocilin and did not promote clearance of any tested mutant myocilins. Although the Q368X OLF mutant is misfolded, the crystal structure of the A427T OLF mutant showed modest perturbations that were largely confined to the mutation site. Our study demonstrates that a full range of misfolded states of mutant myocilin can present challenges for protein quality control clearance pathways and expands the range of defects known to impair mutant myocilin clearance.
- 1 October 2026
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 19 (10)
Open AccessTrabecular meshwork cellular mis-trafficking of near-native and premature stop variants in glaucoma-relevant myocilin
Mutations in the myocilin olfactomedin (OLF) domain can cause vision loss in glaucoma by inducing protein misfolding in trabecular meshwork cells. However, not all mutations are causal for the disease. Here, we compare the cellular behaviors of two variants with uncertain contribution to glaucoma – namely, the missense variant A427T and premature stop variant Q368X – to those of wild type (WT) and disease variant Y437H. When expressed in an inducible immortalized trabecular meshwork cell line, inhibition of the proteasome rerouted WT myocilin from endoplasmic reticulum-associated degradation to autophagy. By contrast, neither Y437H, A427T nor Q368X could be rerouted for degradation. Conversely, inhibition of autophagy caused accumulation of WT myocilin and did not promote clearance of any tested mutant myocilins. Although the Q368X OLF mutant is misfolded, the crystal structure of the A427T OLF mutant showed modest perturbations that were largely confined to the mutation site. Our study demonstrates that a full range of misfolded states of mutant myocilin can present challenges for protein quality control clearance pathways and expands the range of defects known to impair mutant myocilin clearance.
- Open Access
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S97
Abstract 1688: Characterization of severe glaucoma-associated myocilin mutations in an engineered protein scaffold
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S97
Open AccessAbstract 1688: Characterization of severe glaucoma-associated myocilin mutations in an engineered protein scaffold
- Open Access
- 1 January 2023
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 16 (1)
Quantitative differentiation of benign and misfolded glaucoma-causing myocilin variants on the basis of protein thermal stability
Accurate predictions of the pathogenicity of mutations associated with genetic diseases are key to the success of precision medicine. Inherited missense mutations in the myocilin (MYOC) gene, within its olfactomedin (OLF) domain, constitute the strongest genetic link to primary open-angle glaucoma via a toxic gain of function, and thus MYOC is an attractive precision-medicine target. However, not all mutations in MYOC cause glaucoma, and common variants are expected to be neutral polymorphisms. The Genome Aggregation Database (gnomAD) lists ∼100 missense variants documented within OLF, all of which are relatively rare (allele frequency <0.001%) and nearly all are of unknown pathogenicity. To distinguish disease-causing OLF variants from benign OLF variants, we first characterized the most prevalent population-based variants using a suite of cellular and biophysical assays, and identified two variants with features of aggregation-prone familial disease variants. Next, we considered all available biochemical and clinical data to demonstrate that pathogenic and benign variants can be differentiated statistically based on a single metric: the thermal stability of OLF. Our results motivate genotyping MYOC in patients for clinical monitoring of this widespread, painless and irreversible ocular disease.
- 1 January 2023
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 16 (1)
Open AccessQuantitative differentiation of benign and misfolded glaucoma-causing myocilin variants on the basis of protein thermal stability
Accurate predictions of the pathogenicity of mutations associated with genetic diseases are key to the success of precision medicine. Inherited missense mutations in the myocilin (MYOC) gene, within its olfactomedin (OLF) domain, constitute the strongest genetic link to primary open-angle glaucoma via a toxic gain of function, and thus MYOC is an attractive precision-medicine target. However, not all mutations in MYOC cause glaucoma, and common variants are expected to be neutral polymorphisms. The Genome Aggregation Database (gnomAD) lists ∼100 missense variants documented within OLF, all of which are relatively rare (allele frequency <0.001%) and nearly all are of unknown pathogenicity. To distinguish disease-causing OLF variants from benign OLF variants, we first characterized the most prevalent population-based variants using a suite of cellular and biophysical assays, and identified two variants with features of aggregation-prone familial disease variants. Next, we considered all available biochemical and clinical data to demonstrate that pathogenic and benign variants can be differentiated statistically based on a single metric: the thermal stability of OLF. Our results motivate genotyping MYOC in patients for clinical monitoring of this widespread, painless and irreversible ocular disease.
- 24 June 2021
- Published by Wiley in Human Mutation
- Vol. 42 (8) , 903-946
Common and rare myocilin variants: Predicting glaucoma pathogenicity based on genetics, clinical, and laboratory misfolding data
Rare variants of the olfactomedin domain of myocilin are considered causative for inherited, early-onset open angle glaucoma, with a misfolding toxic gain of function pathogenic mechanism detailed by 20 years of laboratory research. Myocilin variants are documented in the scientific literature and identified through large-scale genetic sequencing projects such as those curated in the Genome Aggregation Database (gnomAD). In the absence of key clinical and laboratory information, however, the pathogenicity of any given variant is not clear, because glaucoma is a heterogeneous and prevalent age-onset disease, and common variants are likely benign. In this review, we reevaluate the likelihood of pathogenicity for the ~100 non-synonymous missense, insertion-deletion, and premature termination myocilin olfactomedin variants documented in the literature. We integrate available clinical, laboratory cellular, biochemical and biophysical data, the olfactomedin domain structure, and population genetics data from gnomAD. Of the variants inspected, ~50% can be binned based on a preponderance of data, leaving many of uncertain pathogenicity that motivate additional studies. Ultimately, the approach of combining metrics from different disciplines will likely resolve outstanding complexities regarding the role of this misfolding-prone protein within the context of a multifactorial and prevalent ocular disease, and pave the way for new precision medicine therapeutics.
- 24 June 2021
- Published by Wiley in Human Mutation
- Vol. 42 (8) , 903-946
Common and rare myocilin variants: Predicting glaucoma pathogenicity based on genetics, clinical, and laboratory misfolding data
Rare variants of the olfactomedin domain of myocilin are considered causative for inherited, early-onset open angle glaucoma, with a misfolding toxic gain of function pathogenic mechanism detailed by 20 years of laboratory research. Myocilin variants are documented in the scientific literature and identified through large-scale genetic sequencing projects such as those curated in the Genome Aggregation Database (gnomAD). In the absence of key clinical and laboratory information, however, the pathogenicity of any given variant is not clear, because glaucoma is a heterogeneous and prevalent age-onset disease, and common variants are likely benign. In this review, we reevaluate the likelihood of pathogenicity for the ~100 non-synonymous missense, insertion-deletion, and premature termination myocilin olfactomedin variants documented in the literature. We integrate available clinical, laboratory cellular, biochemical and biophysical data, the olfactomedin domain structure, and population genetics data from gnomAD. Of the variants inspected, ~50% can be binned based on a preponderance of data, leaving many of uncertain pathogenicity that motivate additional studies. Ultimately, the approach of combining metrics from different disciplines will likely resolve outstanding complexities regarding the role of this misfolding-prone protein within the context of a multifactorial and prevalent ocular disease, and pave the way for new precision medicine therapeutics.
- Open Access
- 24 January 2018
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 12, 10
A Metadata Analysis of Oxidative Stress Etiology in Preclinical Amyotrophic Lateral Sclerosis: Benefits of Antioxidant Therapy
Oxidative stress, induced by an imbalance of free radicals, incites neurodegeneration in Amyotrophic Lateral Sclerosis (ALS). In fact, a mutation in antioxidant enzyme superoxide dismutase 1 (SOD1) accounts for 20% of familial ALS cases. However, the variance among individual studies examining ALS oxidative stress clouds corresponding conclusions. Therefore, we construct a comprehensive, temporal view of oxidative stress and corresponding antioxidant therapy in preclinical ALS by mining published quantitative experimental data and performing metadata analysis of 41 studies. In vitro aggregate analysis of innate oxidative stress inducers, glutamate and hydrogen peroxide, revealed 70–90% of cell death coincides to inducer exposure equivalent to 30–50% peak concentration (p < 0.05). A correlative plateau in cell death suggests oxidative stress impact is greatest in early-stage neurodegeneration. In vivo SOD1-G93A transgenic ALS mouse aggregate analysis of heat shock proteins (HSPs) revealed HSP levels are 30% lower in muscle than spine (p < 0.1). Overall spine HSP levels, including HSP70, are mildly upregulated in SOD1-G93A mice compared to wild type, but not significantly (p > 0.05). Thus, innate HSP compensatory responses to oxidative stress are simply insufficient, a result supportive of homeostatic system instability as central to ALS etiology. In vivo aggregate analysis of antioxidant therapy finds SOD1-G93A ALS mouse survival duration significantly increases by 11.2% (p << 0.001) but insignificantly decreases onset age by 2%. Thus, the aggregate antioxidant treatment effect on survival in preclinical ALS is not sufficient to overcome clinical heterogeneity, which explains the literature disparity between preclinical and clinical antioxidant survival benefit. The aggregate effect sizes on preclinical ALS survival and onset illustrate that present antioxidants, alone, are not sufficient to halt ALS, which underscores its multi-factorial nature. Nonetheless, antioxidant-treated SOD1-G93A ALS mice have significantly increased motor performance (p < 0.05) measured via rotarod. With a colossal aggregate preclinical effect size average of 59.6%, antioxidants are promising for increasing function/quality of life in clinical ALS patients, a premise worth exploration via low-risk nutritional supplements. Finally, more direct, quantitative measures of oxidative stress, antioxidant levels and bioavailability are key to developing powerful antioxidant therapeutics that can assert measurable impacts on redox homeostasis in the brain and spinal cord.
- 24 January 2018
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 12, 10
Open AccessA Metadata Analysis of Oxidative Stress Etiology in Preclinical Amyotrophic Lateral Sclerosis: Benefits of Antioxidant Therapy
Oxidative stress, induced by an imbalance of free radicals, incites neurodegeneration in Amyotrophic Lateral Sclerosis (ALS). In fact, a mutation in antioxidant enzyme superoxide dismutase 1 (SOD1) accounts for 20% of familial ALS cases. However, the variance among individual studies examining ALS oxidative stress clouds corresponding conclusions. Therefore, we construct a comprehensive, temporal view of oxidative stress and corresponding antioxidant therapy in preclinical ALS by mining published quantitative experimental data and performing metadata analysis of 41 studies. In vitro aggregate analysis of innate oxidative stress inducers, glutamate and hydrogen peroxide, revealed 70–90% of cell death coincides to inducer exposure equivalent to 30–50% peak concentration (p < 0.05). A correlative plateau in cell death suggests oxidative stress impact is greatest in early-stage neurodegeneration. In vivo SOD1-G93A transgenic ALS mouse aggregate analysis of heat shock proteins (HSPs) revealed HSP levels are 30% lower in muscle than spine (p < 0.1). Overall spine HSP levels, including HSP70, are mildly upregulated in SOD1-G93A mice compared to wild type, but not significantly (p > 0.05). Thus, innate HSP compensatory responses to oxidative stress are simply insufficient, a result supportive of homeostatic system instability as central to ALS etiology. In vivo aggregate analysis of antioxidant therapy finds SOD1-G93A ALS mouse survival duration significantly increases by 11.2% (p << 0.001) but insignificantly decreases onset age by 2%. Thus, the aggregate antioxidant treatment effect on survival in preclinical ALS is not sufficient to overcome clinical heterogeneity, which explains the literature disparity between preclinical and clinical antioxidant survival benefit. The aggregate effect sizes on preclinical ALS survival and onset illustrate that present antioxidants, alone, are not sufficient to halt ALS, which underscores its multi-factorial nature. Nonetheless, antioxidant-treated SOD1-G93A ALS mice have significantly increased motor performance (p < 0.05) measured via rotarod. With a colossal aggregate preclinical effect size average of 59.6%, antioxidants are promising for increasing function/quality of life in clinical ALS patients, a premise worth exploration via low-risk nutritional supplements. Finally, more direct, quantitative measures of oxidative stress, antioxidant levels and bioavailability are key to developing powerful antioxidant therapeutics that can assert measurable impacts on redox homeostasis in the brain and spinal cord.